Author:
Eskian Mahsa,Khorasanizadeh MirHojjat,Kraeber-Bodere Francoise,Rezaei Nima
Reference80 articles.
1. Patients older than 65 years with non-Hodgkin lymphoma are suitable for treatment with (90)Yttrium-Ibritumumab tiuxetan: a single-Institution experience;Andrade-Campos;Clin. Lymphoma Myeloma Leuk.,2015
2. Radioimmunotherapy effective first-line treatment for non-Hodgkin's lymphoma;Anon;Oncology (Williston Park),2000
3. 90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab;Aurer;Lijec. Vjesn.,2006
4. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies;Azinovic;Cancer Immunol. Immunother.,2006
5. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience;Bienert;Eur. J. Nucl. Med. Mol. Imaging,2005
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献